# **O** Tribioscience

### Sitravatinib, Multikinase inhibitor / Immuno-oncology agent

Catalog	Unit
TBI4826-5MG	5 mg
TBI4826-25MG	25 mg

## **Product Details**

Formal Name: 1-N'-[3-Fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Alternate Names: MGCD516 Molecular Formula:  $C_{33}H_{29}F_2N_5O_4S$ Formula Weight: 629.68 CAS Number: 1123837-84-2 Purity: >98% Formulation: powder Solubility: Soluble in DMSO (up to at least 25 mg/ml) or in Ethanol (up to at least 25 mg/ml) Storage: -20°C Stability:  $\geq$  1 year.

#### **Applications**

Multikinase inhibitor / Immuno-oncology agent

#### **Functions**

Sitravatinib is a broad spectrum receptor tyrosine kinase inhibitor. Its targets include Axl, c-Met, PDGFR, VEGFR, Ephrin receptor family, and FLT3 among others at nanomolar levels. Sitravatinib has been tested in mouse models of sarcoma and showed better efficacy than both imatinib and crizotinib. Because of its unique kinase inhibition profile (especially that of TAM receptors), it has been used to restore response to anti-PD-1 therapy (nivolumab) in NSCLC patients. Sitravatinib was able to significantly alter the immunosuppressive tumor microenvironment in three preclinical tumor models to enhance the effects of PD-1 blockade therapy.

#### **Application Procedures**

First dissolved in DMSO (up to at least 25 mg/ml) or in Ethanol (up to at least 25 mg/ml), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.

For research use only.